Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 418
- Registration Number
- NCT06415773
- Locations
- π¨π³
Peking University People's Hospital, Beijing, China
π¨π³Binzhou Medical University Hospital, Binzhou, China
π¨π³The Second Norman Bethune Hospital of Jilin University, Changchun, China
A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 113
- Registration Number
- NCT06411275
- Locations
- π¨π³
Liaocheng People's Hospital, Liaocheng, China
π¨π³Affiliated Hospital of Jiangsu University, Zhenjiang, China
π¨π³The First People's Hospital of Changde City, Changde, China
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 551
- Registration Number
- NCT06353347
- Locations
- π¨π³
Beijing Pinggu Hospital, Beijing, China
π¨π³The Second Norman Bethune Hospital of Jilin University, Changchun, China
π¨π³Hunan Provincial People's Hospital, Changsha, China
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 408
- Registration Number
- NCT06350890
- Locations
- π¨π³
Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China
π¨π³Cangzhou Central Hospital, Cangzhou, Hebei, China
π¨π³Beijing Pinggu Hospital, Beijing, Beijing, China
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 218
- Registration Number
- NCT05623189
- Locations
- πΊπΈ
Piedmont Health Care, Atlanta, Georgia, United States
πΊπΈMercy Medical Center, Baltimore, Maryland, United States
πΊπΈClinical Pharmacology of Miami, LLC, Miami, Florida, United States
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
- Conditions
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT04604652
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈNorthshore University Hospital, Manhasset, New York, United States
πΊπΈLiver Institute Northwest, Seattle, Washington, United States
A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Registration Number
- NCT03678480
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 101
- Registration Number
- NCT03656744
- Locations
- πΊπΈ
Excel Medical Clinical Trials, Boca Raton, Florida, United States
πΊπΈHarborview Medical Center, Seattle, Washington, United States
πΊπΈGastro One, Germantown, Tennessee, United States
A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT03381287
- Locations
- π¦πΊ
Q-Pharm Pty Ltd., Herston, Queensland, Australia
π¦πΊCMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
π¦πΊLinear Clinical Research, Nedlands, Western Australia, Australia
A POC and Dose-Ranging Study of HTD1801 in PSC Patients
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 59
- Registration Number
- NCT03333928
- Locations
- π¨π¦
Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Ontario, Canada
πΊπΈMercy Medical Center, Baltimore, Maryland, United States
πΊπΈUniversity of Miami, Miami, Florida, United States